
A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: A combined analysis of 10 EORTC trials
Keywords: بقا بدون پیشرفت; Cytostatic agents; Nomogram; Mesothelioma; Clinical trials; Phase II; Prognostic index; Progression-free survival